In this issue:
- Daratumumab + RVD for MM
- Peripheral blood stem cell mobilisation following RVD induction for MM
- Real-world outcomes for VTD-PACE in relapsed/ refractory MM
- Lenalidomide-dexamethasone maintenance ± ixazomib, tailored by MRD status, in myeloma
- Isatuximab + KRD for high risk newly diagnosed MM
- Second-line CAR T-cell therapy in DLBCL
- Second neoplasms in APML
- OS in progressive classical Hodgkin lymphoma after autologous SCT
- Consolidative RT for residual fluorodeoxyglucose activity after CAR T-cells in non Hodgkin lymphoma
- Impact of cumulative brentuximab vedotin dose on outcomes in advanced-stage Hodgkin lymphoma
Please login below to download this issue (PDF)